Immunogenicity of herpes simplex virus type 1 mutants containing deletions in one or more α-genes: ICP4, ICP27, ICP22, and ICP0

Virology

Volumn 256, Issue 2, 1999, Pages 258-269

  Brehm, Michael ^a   Samaniego, Lorna A ^b   Bonneau, Robert H ^a   Deluca, Neal A ^b   Tevethia, Satvir S ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIBONUCLEOTIDE REDUCTASE; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; CELL MEDIATED CYTOTOXICITY; CYTOTOXIC T LYMPHOCYTE; GENE DELETION; GENE EXPRESSION; GENE THERAPY; HERPES SIMPLEX VIRUS 1; IMMUNIZATION; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MEMORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS MUTANT; VIRUS REPLICATION;

ANIMALIA; DNA VIRUSES; HERPES; HUMAN HERPESVIRUS 1;

EID: 0033541364     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1999.9653     Document Type: Article

References (61)

1. + cytolytic T cell responses. J. Exp. Med. 182:1995;1663-1671.
2. Bevan M. J. Antigen presentation to cytotoxic T lymphocytes in vivo. J. Exp. Med. 182:1995;639-641.
3. Blaney J. E. Jr., Nobusawa E., Brehm M. A., Bonneau R. H., Mylin L. M., Fu T. M., Kawaoka Y., Tevethia S. S. Immunization with a single major histocompatibility complex class I-restricted cytotoxic T-lymphocyte recognition epitope of herpes simplex virus type 2 confers protective immunity. J. Virol. 72:1998;9567-9574.
4. Bonneau R. H., Jennings S. R. Modulation of acute and latent herpes simplex virus infection in C57BL/6 mice by adoptive transfer of immune lymphocytes with cytolytic activity. J. Virol. 63:1989;1480-1484.
5. Bonneau R. H., Jennings S. R. Herpes simplex virus-specific cytolytic T lymphocytes restricted to a normally low responder H-2 allele are protective in vivo. Virology. 174:1990;599-604.
6. b-restricted, HSV-1- and HSV-2-cross-reactive cytotoxic T lymphocyte clones. Virology. 195:1993;62-70.
7. Braciale T. J., Yap K. L. Role of viral infectivity in the induction of influenza virus-specific cytotoxic T cells. J. Exp. Med. 147:1978;1236-1252.
8. Breakefield X. O., DeLuca N. A. Herpes simplex virus as vectors for neurons. Desnick Robert J. Treatment of Genetic Disease. 1991;287-320 Churchill Livingstone, New York.
9. + cytotoxic T-lymphocyte response and confers a level of protection comparable to that of wild-type HSV-1. J. Virol. 71:1997;3534-3544.
10. Carter V. C., Schaffer P. A., Tevethia S. S. The involvement of herpes simplex virus type-1 glycoproteins in cell mediated immunity. J. Immunol. 126:1981;1655-1660.
11. Chiocca E. A., Choi B. B., Cai W. Z., DeLuca N. A., Schaffer P. A., DiFiglia M., Breakefield X. O., Martuza R. L. Transfer and expression of the lacZ gene in rat brain neurons mediated by herpes simplex virus mutants. New Biol. 2:1990;739-746.
12. DeLuca N. A., McCarthy A. M., Schaffer P. A. Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J. Virol. 56:1985;558-570.
13. Everett R. D. Trans activation of transcription by herpes virus products: Requirement for two HSV-1 immediate-early polypeptides for maximum activity. EMBO J. 3:1984;3135-3141.
14. Everett R. D. Construction and characterization of herpes simplex virus type 1 mutants with defined lesions in immediate early gene 1. J. Gen. Virol. 70:1989;1185-1202.
15. Farrell H. E., McLean C. S., Harley C., Efstathiou S., Inglis S., Minson A. C. Vaccine potential of a herpes simplex virus type-1 mutant with an essential glycoprotein deleted. J. Virol. 68:1994;927-932.
16. Fu T.-M., Bonneau R. H., Tevethia M. J., Tevethia S. S. Simian virus 40 T antigen as a carrier for the expression of cytotoxic T-lymphocyte recognition epitopes. J. Virol. 67:1993;6866-6871.
17. Glorioso J. C., DeLuca N. A., Fink D. J. Development and application of herpes simplex virus vectors for human gene therapy. Annu. Rev. Microbiol. 49:1995;675-710.
18. Hanke T., Graham F. L., Rosenthal K. L., Johnson D. C. Identification of an immunodominant cytotoxic T-lymphocyte recognition site in glycoprotein B of herpes simplex virus by using recombinant adenovirus vectors and synthetic peptides. J. Virol. 65:1991;1177-1186.
19. Jennings S. R., Bonneau R. H., Smith P. M., Wolcott R. M., Chervenak R. CD4-positive T lymphocytes are required for the generation of the primary but not the secondary CD8-positive cytolytic T lymphocyte response to herpes simplex virus in C57BL/6 mice. Cell. Immunol. 133:1991;234-252.
20. Johnson D. C., Spear P. G. Monensin inhibits the processing of herpes simplex virus glycoproteins, their transport to the cell surface, and egress of virions from infected cells. J. Virol. 43:1982;1102-1112.
21. Jondal M., Schirmbeck R., Reinmann J. MHC class I-restricted CTL responses to exogenous antigen. Immunity. 5:1996;295-302.
22. Kierstead T. D., Tevethia M. J. Association of p53 binding and immortalization of primary C57BL/6 mouse embryo fibroblasts by using simian virus 40 T-antigen mutants bearing internal overlapping deletion mutations. J. Virol. 67:1993;1817-1829.
23. Koszinowski U., Gething M. J., Waterfield M. T-cell cytotoxicity in the absence of viral protein synthesis in target cells. Nature (London). 267:1977;160-163.
24. Kovacsovics-Bankowski M., Rock K. L. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science. 267:1995;243-245.
25. Kuklin N. A., Daheshia M., Marconi P. C., Krisky D. M., Rouse R. J. D., Glorioso J. C., Manican E., Rouse B. T. Modulation of mucosal and systemic immunity by enteric administration of nonreplicating herpes simplex virus expressing cytokines. Virology. 240:1998;245-253.
26. Lawman M. B., Rouse B. T., Courtney R. J., Walker R. D. Cell mediated immunity against herpes simplex virus: Induction of cytotoxic T lymphocytes. Infect. Immun. 27:1980;133-139.
27. Liu T., Zhou X., Orvell C., Lederer E., Ljunggren H. G., Jondal M. Heat-inactivated sendai virus can enter multiple MHC class I processing pathways and generate cytotoxic T lymphocyte responses in vivo. J. Immunol. 154:1995;3147-3155.
28. McCarthy A. M., McMahan L., Schaffer P. A. Herpes simplex virus type 1 ICP27 deletion mutants exhibit altered patterns of transcription and are DNA deficient. J. Virol. 63:1989;18-27.
29. McLean C. S., Erturk M., Jennings R., Challanain D. N., Minson A. C., Duncan I., Boursnell M. E. G., Inglis S. C. Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1. J. Infect. Dis. 170:1994;1100-1109.
30. Morrison L. A., Knipe D. M. Immunization with replication-defective mutants of herpes simplex virus type 1: Sites of immune intervention in pathogenesis of challenge virus infection. J. Virol. 68:1994;689-696.
31. Morrison L. A., Knipe D. M. Mechanisms of immunization with a replication-defective mutant of herpes simplex virus 1. Virology. 220:1996;402-413.
32. Morrison L. A., Knipe D. M. Contributions of antibody and T cell subsets to protection elicited by immunization with a replication-defective mutant of herpes simplex virus type 1. Virology. 239:1997;315-326.
33. Nguyen L. H., Knipe D. M., Finberg R. W. Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection. J. Virol. 66:1992;7067-7072.
34. Offit P. A., Greenberg H. B., Dudzik K. I. Rotavirus-specific protein synthesis is not necessary for recognition of infected cells by virus specific cytotoxic T lymphocytes. J. Virol. 63:1989;3279-3283.
35. Pfizenmaier K., Jung H., Starzinski-Powitz A., Rollinghoff M., Falks D., Wagner H. The role of T cells in anti-herpes immunity. I. Induction of antigen-specific cytotoxic T lymphocytes. J. Immunol. 119:1977a;939-944.
36. Pfizenmaier K., Starzinski-Powitz A., Rollinghoff M., Wagner H. T-cell-mediated cytotoxicity against herpes simplex virus-infected target cells. Nature (London). 265:1977b;630-632.
37. Pretell J., Greenfield R. S., Tevethia S. S. Biology of simian virus 40 (SV40) transplantation rejection antigen (TrAg). V. In vitro demonstration of SV40 TrAg in SV40-infected permissive mouse cells by the lymphocyte mediated cytotoxicity assay. Virology. 97:1979;32-41.
38. Reddehase M. J., Keil G. M., Koszinowski U. H. The cytolytic T lymphocyte response to the murine cytomegalovirus II. Detection of virus replication stage-specific antigens by separate populations of in vivo active cytolytic T lymphocyte precursors. Eur. J. Immunol. 14:1984;56-61.
39. Rice S. A., Long M. C., Lam V., Schaffer P. A., Spencer C. A. Herpes simplex virus immediate-early protein ICP22 is required for viral modification of host RNA polymerase II and establishment of the normal viral transcription program. J. Virol. 69:1995;5550-5559.
40. Riddell S. R., Rabin M., Geballe A. P., Britt W. J., Greenberg P. D. Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. J. Immunol. 146:1991;2795-2804.
41. Rock K. L. A new foreign policy: MHC class I molecules monitor the outside world. Immunol. Today. 17:1996;131-137.
42. Rock K. L., Gamble S., Rothstein L. Presentation of exogenous antigen with class I major histocompatibility complex molecules. Science. 249:1990;918-921.
43. Roscoe D. M., Ishikawa K., Lyles D. S. Role of de novo protein synthesis in target cells recognized by cytotoxic T lymphocytes specific for vesicular stomatitis virus. J. Virol. 65:1991;6856-6861.
44. Salvucci L. A., Bonneau R. H., Tevethia S. S. Polymorphism within the herpes simplex virus type 1 (HSV-1) ribonucleotide reductase large subunit (ICP6) confers type specificity for recognition by HSV type 1-specific cytotoxic T lymphocytes. J. Virol. 69:1995;1122-1131.
45. Samaniego L. A., Webb A. L., DeLuca N. A. Functional interactions between herpes simplex virus immediate-early proteins during infection: Gene expression as a consequence of ICP27 and different domains of ICP4. J. Virol. 69:1995;5705-5715.
46. Samaniego L. A., Wu N., DeLuca N. A. The herpes simplex virus immediate-early protein ICP0 affects transcription from the viral genome and infected-cell survival in the absence of ICP4 and ICP27. J. Virol. 71:1997;4614-4625.
47. Schirmbeck R., Zerrahn J., Kuhrober A., Deppert W., Reinmann J. Immunization of mice with the N-terminal (1-272) fragment of simian virus 40 large T antigen (without adjuvants) specifically primes cytotoxic T lymphocytes. Eur. J. Immunol. 23:1993;1528-1534.
48. + cytotoxic T lymphocytes in mice. Eur. J. Immunol. 22:1992;759-766.
49. Schmid D. S., Rouse B. T. The role of T cell immunity in control of herpes simplex virus. Rouse Barry T. Current Topics in Microbiology and Immunology: Herpes Simplex Virus. 1992;57-74 Springer-Verlag, New York.
50. Showalter S. D., Zweig M., Hampar B. Monoclonal antibodies to herpes simplex virus type 1 proteins, including the immediate-early protein ICP4. J. Virol. 34:1981;684-692.
51. Simmons A., Tscharke D. C. Anti-CD8 impairs clearance of herpes simplex virus from the nervous system: Implications for the fate of virally infected neurons. J. Exp. Med. 175:1992;1337-1344.
52. Smith P. M., Wolcott R. M., Chervenak R., Jennings S. R. Control of acute cutaneous herpes simplex virus infection: T cell-mediated viral clearance is dependent upon interferon-gamma (IFN-gamma). Virology. 202:1994;76-88.
53. Tanaka Y., Tevethia S. S. In vitro selection of SV40 T antigen epitope loss variants by site specific cytotoxic T lymphocyte clones. J. Immunol. 140:1988;4348-4354.
54. Tanaka Y., Tevethia S. S. Loss of immunorecessive cytotoxic T lymphocyte determinant V on SV40 T antigen following cocultivation with site-specific cytotoxic T lymphocyte clone Y-5. Intervirology. 31:1990;197-202.
55. Tevethia S. S., Flyer D. C., Tijan R. Biology of simian virus 40 (SV40) transplantation antigen (TrAg). VI. Mechanisms of induction of SV40 transplantation immunity in mice by purified SV40 T antigen (D2 protein). Virology. 107:1980;13-23.
56. Thomsen D. R., Roof L. L., Homa F. L. Assembly of herpes simplex virus (HSV) intermediate capsids in insect cells infected with recombinant baculoviruses expressing HSV capsid proteins. J. Virol. 68:1994;2442-2457.
57. + herpes simplex virus-specific cytotoxic T-lymphocyte clones recognize diverse virion protein antigens. J. Virol. 66:1992;1622-1634.
58. Ward P. L., Roizman B. Herpes simplex genes: The blueprint of a successful human pathogen. Trends Genet. 10:1994;267-274.
59. Wu N., Watkins S. C., Schaffer P. A., DeLuca N. A. Prolonged gene expression and cell survival after infection by a herpes simplex virus mutant defective in the immediate-early genes encoding ICP4, ICP27, and ICP22. J. Virol. 70:1996;6358-6369.
60. Yang Y., Jooss K. U., Su Q., Ertl H. C., Wilson J. M. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther. 3:1996;137-144.
61. Yewdell J. W., Bennink J. R., Hosaka Y. Cells process exogenous antigen for recognition by cytotoxic T lymphocytes. Science. 239:1988;637-640.